Fda Nih 2024 D1s17 Q

The last of three Q&A discussion panels from the

This presentation provided an overview of CDRH's Medical Device Development Tools (MDDT) Program and explained what ...

The last of three Q&A discussion panels for day one of the Generic Drug Forum

This presentation explored medical device coverage initiatives and the role of the Payor Communication Task Force in connecting ...

This presentation outlined CDER's clinical considerations for First-in-Human trials and presented general good practices for FIH ...

This presentation provided information about the Small Business and Industry Assistance (SBIA) and its mission. Topics ...

This presentation provided guidance on nonclinical assessment of Cell and Gene Therapy (CGT) products to support IND ...

The first of three Q&A discussion panels from the

This presentation explored the essential components of Chemistry, Manufacturing, and Controls (CMC) within pharmaceutical ...

This presentation provided information on the National Cancer Institute's Small Business Innovation Research (SBIR) ...

This presentation provided comprehensive guidance on CDER's nonclinical resources for approaching First-in-Human (FIH) ...

The second of three Q&A discussion panels from the

This presentation highlighted key clinical regulatory issues encountered during early-phase development of cellular and gene ...

NIH

This presentation explained the role and function of the Division of Industry and Consumer Education (DICE) within the

This presentation introduced CBER's Manufacturers Assistance and Technical Training Branch (MATTB) and explained their ...

This inaugural webinar was a collaborative effort between

This presentation discussed a rundown of the Do's and Don'ts from

NIH

NIH